Nursing observation of 40 cycles of Opdivo in an elderly patient with advanced heterochronous esophageal cancer who tested negative for programmed death ligand 1

Hongyu Kuang, Haiyan Shi
{"title":"Nursing observation of 40 cycles of Opdivo in an elderly patient with advanced heterochronous esophageal cancer who tested negative for programmed death ligand 1","authors":"Hongyu Kuang, Haiyan Shi","doi":"10.3760/CMA.J.ISSN.1672-7088.2020.07.014","DOIUrl":null,"url":null,"abstract":"Objective \nTo observe the effect of long cycle application of Opdivo in patients with esophageal cancer whose programmed death ligand 1(PD-L1) test was negative and the nursing care of its related adverse reactions. \n \n \nMethods \nFor an elderly patient with advanced heterochronous esophageal cancer with only 40 cycles of Opdivo and negative PD-L1, detailed individualized nursing measures were made from the aspects of medication management, psychological guidance and observation of adverse reactions. \n \n \nResults \nThe vital signs of the patients were stable, the KPS score was increased from 60 to 80, the carcinoembryonic antigen was reduced from 15.36 μg/L to 9.45 μg /L, and the adverse reactions such as immune dermatitis and hypothyroidism were relieved. \n \n \nConclusions \nThe nursing experience of patients treated with Opdivo for a long period has been obtained, and the corresponding nursing evidence support has been provided for the clinical application of navumab in the treatment of tumor. \n \n \nKey words: \nSquamous cell carcinoma of esophagus; Programmed death ligand 1; Monotherapy; Opdivo","PeriodicalId":22999,"journal":{"name":"The Journal of practical nursing","volume":"31 1","pages":"550-552"},"PeriodicalIF":0.0000,"publicationDate":"2020-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Journal of practical nursing","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3760/CMA.J.ISSN.1672-7088.2020.07.014","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Objective To observe the effect of long cycle application of Opdivo in patients with esophageal cancer whose programmed death ligand 1(PD-L1) test was negative and the nursing care of its related adverse reactions. Methods For an elderly patient with advanced heterochronous esophageal cancer with only 40 cycles of Opdivo and negative PD-L1, detailed individualized nursing measures were made from the aspects of medication management, psychological guidance and observation of adverse reactions. Results The vital signs of the patients were stable, the KPS score was increased from 60 to 80, the carcinoembryonic antigen was reduced from 15.36 μg/L to 9.45 μg /L, and the adverse reactions such as immune dermatitis and hypothyroidism were relieved. Conclusions The nursing experience of patients treated with Opdivo for a long period has been obtained, and the corresponding nursing evidence support has been provided for the clinical application of navumab in the treatment of tumor. Key words: Squamous cell carcinoma of esophagus; Programmed death ligand 1; Monotherapy; Opdivo
1例程序性死亡配体1阴性的老年晚期异时性食管癌患者使用Opdivo 40个周期的护理观察
目的观察长周期应用Opdivo治疗程序性死亡配体1(PD-L1)试验阴性食管癌患者的效果及相关不良反应的护理。方法对1例老年晚期异时性食管癌患者,仅使用40个周期Opdivo, PD-L1阴性,从用药管理、心理指导、不良反应观察等方面制定详细的个性化护理措施。结果患者生命体征稳定,KPS评分由60分提高到80分,癌胚抗原由15.36 μg/L降低到9.45 μg/L,免疫皮炎、甲状腺功能减退等不良反应得到缓解。结论获得了Opdivo长期治疗患者的护理经验,为navdivo在肿瘤治疗中的临床应用提供了相应的护理证据支持。关键词:食管鳞状细胞癌;程序性死亡配体1;单一疗法;Opdivo
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信